Lisa Bomgaars
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lisa Bomgaars has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Elizabeth Chalmers
Royal Hospital for Children Glasgow UK
2 shared publications Jacqueline Halton
Division of Hematology/Oncology, Children’s Hospital of Eastern Ontario, University of Ottawa, Ottawa, ON, Canada
2 shared publicationsJudy Felgenhauer
10Pediatric Hematology & Oncology, Sacred Heart Medical Center and Children’s Hospital, Spokane, WA
2 shared publications- Leonardo Rodrigues Brandao
Hospital for Sick Children, University of Toronto
2 shared publications - Manuela Albisetti
Abteilung Hämatologie, Universitäts-Kinderspital Zürich – Eleonorenstiftung, Zürich, Switzerland
2 shared publications Monika Simetzberger
13Clinical Development and Operations, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
2 shared publications
Latest Publications
- Open Access
- 27 September 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (22) , 5908-5923
Dabigatran in the treatment and secondary prophylaxis of venous thromboembolism in children with thrombophilia
In the phase 2b/3 DIVERSITY trial, 3 months treatment with dabigatran was noninferior to standard of care (SOC) for acute venous thromboembolism (VTE) in children. In a single-arm, phase 3, secondary VTE prevention study, up to 12 months dabigatran use was associated with favorable safety. Dabigatran is approved by the European Medicines Agency and US Food and Drug Administration for pediatric indications. We assessed primary composite efficacy (complete thrombus resolution and freedom from VTE recurrence/VTE-related death) in subgroups with thrombophilia vs those with negative/unknown thrombophilia status in the DIVERSITY trial and safety in both studies. Thrombophilia types were similar between the DIVERSITY trial (total population) and secondary prevention studies: factor V Leiden, 42% vs 33%; prothrombin mutation (G20210A), 19% vs 17%; antithrombin deficiency, 15% vs 20%; protein C/S deficiency, 23% vs 25%; and antiphospholipid antibodies, 18% vs 20% of patients, respectively. In DIVERSITY, 36% and 22% of thrombophilia subgroup patients treated with dabigatran and SOC, respectively, met the primary end point (Mantel-Haenszel–weighted rate difference, −0.135; 95% confidence interval, −0.36 to 0.08; noninferiority P = .0014); comparable to the total DIVERSITY trial population (46% vs 42%) showing dabigatran noninferiority to SOC. Within this subgroup, numerically fewer patients experienced VTE recurrence or progression of index thrombus in the dabigatran treatment group vs SOC. In the secondary prevention study, VTE recurrence at 12 months occurred in 2.8% of patients with thrombophilia vs 0% with negative/unknown thrombophilia. Safety profiles were consistent with those reported previously. Although they should be interpreted with caution, these exploratory findings suggest dabigatran could be an appropriate long-term anticoagulant for children with thrombophilia. These trials were registered at www.clinicaltrials.gov as #NCT01895777 and #NCT02197416.
- 27 September 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (22) , 5908-5923
Open AccessDabigatran in the treatment and secondary prophylaxis of venous thromboembolism in children with thrombophilia
In the phase 2b/3 DIVERSITY trial, 3 months treatment with dabigatran was noninferior to standard of care (SOC) for acute venous thromboembolism (VTE) in children. In a single-arm, phase 3, secondary VTE prevention study, up to 12 months dabigatran use was associated with favorable safety. Dabigatran is approved by the European Medicines Agency and US Food and Drug Administration for pediatric indications. We assessed primary composite efficacy (complete thrombus resolution and freedom from VTE recurrence/VTE-related death) in subgroups with thrombophilia vs those with negative/unknown thrombophilia status in the DIVERSITY trial and safety in both studies. Thrombophilia types were similar between the DIVERSITY trial (total population) and secondary prevention studies: factor V Leiden, 42% vs 33%; prothrombin mutation (G20210A), 19% vs 17%; antithrombin deficiency, 15% vs 20%; protein C/S deficiency, 23% vs 25%; and antiphospholipid antibodies, 18% vs 20% of patients, respectively. In DIVERSITY, 36% and 22% of thrombophilia subgroup patients treated with dabigatran and SOC, respectively, met the primary end point (Mantel-Haenszel–weighted rate difference, −0.135; 95% confidence interval, −0.36 to 0.08; noninferiority P = .0014); comparable to the total DIVERSITY trial population (46% vs 42%) showing dabigatran noninferiority to SOC. Within this subgroup, numerically fewer patients experienced VTE recurrence or progression of index thrombus in the dabigatran treatment group vs SOC. In the secondary prevention study, VTE recurrence at 12 months occurred in 2.8% of patients with thrombophilia vs 0% with negative/unknown thrombophilia. Safety profiles were consistent with those reported previously. Although they should be interpreted with caution, these exploratory findings suggest dabigatran could be an appropriate long-term anticoagulant for children with thrombophilia. These trials were registered at www.clinicaltrials.gov as #NCT01895777 and #NCT02197416.
- Open Access
- 5 November 2020
- Published by American Society of Hematology in Blood
- Vol. 136 (Supplement) , 35-36
Efficacy and Safety of Dabigatran in the Treatment and Secondary Prophylaxis of Children with Venous Thromboembolism and Thrombophilia
Background: Thrombophilia in children is characterized by hypercoagulability and increased frequency of thrombotic events (Young G, et al. Circulation. 2008;118:1373-1378; Kenet G, et al. Circulation. 2010;121:1838-1847). Recently, phase IIb/III clinical trials in children with venous thromboembolism (VTE) have reported the non-inferiority of dabigatran etexilate (DE) versus standard of care (SOC) for the treatment of acute VTE (Albisetti M, et al. ISTH 2019, Abstract OC 57.3), and a favorable safety profile for DE in secondary VTE prevention in children with persistent VTE risk factor(s) (Brandão LR, et al. Blood. 2020;135:491-504). Aims: To perform a subgroup analysis evaluating the efficacy and safety of DE for the treatment and secondary prophylaxis of VTE in children with thrombophilia in the phase IIb/III DE clinical trials. Methods: In the open-label, phase IIb/III DIVERSITY trial (NCT01895777), children aged from birth to < 18 years (yrs) with an objectively confirmed VTE diagnosis (by imaging studies) initially treated with unfractionated heparin or low-molecular-weight heparin were randomized (2:1) to receive up to 3 months of DE or SOC. Primary composite efficacy endpoint: complete thrombus resolution and freedom from VTE recurrence, or VTE-related death. Safety endpoints included bleeding events (BEs). The open-label, phase III, secondary VTE prevention trial (NCT02197416) treated children aged from > 3 months to < 18 yrs with DE for up to 12 months or less, if the identified VTE clinical risk factor resolved. Eligible children had an objectively confirmed diagnosis of VTE treated with SOC for ≥ 3 months, or had completed DE or SOC treatment in DIVERSITY and had an unresolved clinical VTE risk factor requiring further anticoagulation. Primary endpoints included VTE recurrence and BEs. Thrombophilia status was confirmed according to the definitions used by the local experts. Results: In DIVERSITY, 23.2% of children had thrombophilia; demographics were comparable to the overall population, although they were slightly older (mean [standard deviation] age 13.2 [4.9] vs 11.1 [6.1] years in the overall population; p = 0.005). In children with thrombophilia, DE was found to be non-inferior to SOC for the primary endpoint (similar to the overall population), and more children treated with DE achieved the composite primary endpoint than with SOC (SOC 21.7% vs DE 35.9%; Mantel-Hänszel-weighted difference in rates for SOC minus DE [90% CI] −0.14 [−0.32 to 0.05]; p for non-inferiority = 0.0014), similar to the overall population (Table). Regardless of treatment, VTE recurrence appeared higher in children with thrombophilia than in the overall population, with numerically fewer VTE recurrences reported by children with thrombophilia treated with DE (7.7%) versus SOC (21.7%), although this was not significantly lower (p = 0.13). Numerical differences in residual thrombotic burden between SOC vs DE seen in the overall population appeared to be amplified in children with thrombophilia. Numerically fewer children with thrombophilia treated with DE reported thrombus progression (SOC 13.0% vs DE 5.1%) or stabilization (21.7% vs 10.3%), while more reported partial (34.8% vs 43.6%) or complete thrombus resolution (21.7% vs 35.9%). In the thrombophilia subgroup, BEs appeared to be lower in children treated with DE (SOC 26.1% vs DE 17.9%), while in the overall population BEs with SOC and DE were comparable. In the secondary VTE prevention trial, children with thrombophilia were also slightly older versus the overall population (mean [standard deviation] age 14.1 [3.6] vs 12.8 [4.6] yrs; p = 0.006). In this larger subgroup of children, rates of recurrent VTE at 12 months appeared to be higher in the thrombophilia group (2.8%) compared to the overall population (1.4%) (Table), with BEs largely comparable (27.4% and 22.5%, respectively). Conclusions: Unsurprisingly, numerically more children with thrombophilia appeared to report VTE recurrence, and in DIVERSITY thrombus progression/stabilization also seemed higher compared with the overall population. Compared with the overall populations, these subgroup analyses showed consistent results for DE in children with acute VTE and thrombophilia in the DIVERSITY trial, along with a favorable safety profile of DE for secondary VTE prevention. Disclosures Brandao: Boehringer Ingelheim: Other: Member of a paediatric expert working group. Tartakovsky:Boehringer Ingelheim: Current Employment. Albisetti:Boehringer Ingelheim: Other: Member of a paediatric expert working group; Daiichi Sankyo: Membership on an entity's Board of Directors or advisory committees. Bomgaars:Boehringer Ingelheim: Other: Member of a paediatric expert working group. Chalmers:CSL Behring: Honoraria; Shire/Takeda: Honoraria; Boehringer Ingelheim: Other: Member of a paediatric expert working group; Grifols: Honoraria; Roche: Honoraria; Sobi: Honoraria; Bristol-Myers Squibb: Honoraria. Mitchell:Boehringer Ingelheim: Other: Member of a paediatric expert working group. Luciani:Boehringer Ingelheim: Other: Member of a paediatric expert working group. Lvova:Boehringer Ingelheim: Honoraria. Simetzberger:Boehringer Ingelheim: Current Employment. Sun:Boehringer Ingelheim: Current Employment. Gergei:Boehringer Ingelheim: Current Employment. Brueckmann:Boehringer Ingelheim: Current Employment. Halton:Boehringer Ingelheim: Other: Member of a paediatric expert working group. OffLabel Disclosure: dabigatran etexilate in paediatric VTE
- 5 November 2020
- Published by American Society of Hematology in Blood
- Vol. 136 (Supplement) , 35-36
Open AccessEfficacy and Safety of Dabigatran in the Treatment and Secondary Prophylaxis of Children with Venous Thromboembolism and Thrombophilia
Background: Thrombophilia in children is characterized by hypercoagulability and increased frequency of thrombotic events (Young G, et al. Circulation. 2008;118:1373-1378; Kenet G, et al. Circulation. 2010;121:1838-1847). Recently, phase IIb/III clinical trials in children with venous thromboembolism (VTE) have reported the non-inferiority of dabigatran etexilate (DE) versus standard of care (SOC) for the treatment of acute VTE (Albisetti M, et al. ISTH 2019, Abstract OC 57.3), and a favorable safety profile for DE in secondary VTE prevention in children with persistent VTE risk factor(s) (Brandão LR, et al. Blood. 2020;135:491-504). Aims: To perform a subgroup analysis evaluating the efficacy and safety of DE for the treatment and secondary prophylaxis of VTE in children with thrombophilia in the phase IIb/III DE clinical trials. Methods: In the open-label, phase IIb/III DIVERSITY trial (NCT01895777), children aged from birth to < 18 years (yrs) with an objectively confirmed VTE diagnosis (by imaging studies) initially treated with unfractionated heparin or low-molecular-weight heparin were randomized (2:1) to receive up to 3 months of DE or SOC. Primary composite efficacy endpoint: complete thrombus resolution and freedom from VTE recurrence, or VTE-related death. Safety endpoints included bleeding events (BEs). The open-label, phase III, secondary VTE prevention trial (NCT02197416) treated children aged from > 3 months to < 18 yrs with DE for up to 12 months or less, if the identified VTE clinical risk factor resolved. Eligible children had an objectively confirmed diagnosis of VTE treated with SOC for ≥ 3 months, or had completed DE or SOC treatment in DIVERSITY and had an unresolved clinical VTE risk factor requiring further anticoagulation. Primary endpoints included VTE recurrence and BEs. Thrombophilia status was confirmed according to the definitions used by the local experts. Results: In DIVERSITY, 23.2% of children had thrombophilia; demographics were comparable to the overall population, although they were slightly older (mean [standard deviation] age 13.2 [4.9] vs 11.1 [6.1] years in the overall population; p = 0.005). In children with thrombophilia, DE was found to be non-inferior to SOC for the primary endpoint (similar to the overall population), and more children treated with DE achieved the composite primary endpoint than with SOC (SOC 21.7% vs DE 35.9%; Mantel-Hänszel-weighted difference in rates for SOC minus DE [90% CI] −0.14 [−0.32 to 0.05]; p for non-inferiority = 0.0014), similar to the overall population (Table). Regardless of treatment, VTE recurrence appeared higher in children with thrombophilia than in the overall population, with numerically fewer VTE recurrences reported by children with thrombophilia treated with DE (7.7%) versus SOC (21.7%), although this was not significantly lower (p = 0.13). Numerical differences in residual thrombotic burden between SOC vs DE seen in the overall population appeared to be amplified in children with thrombophilia. Numerically fewer children with thrombophilia treated with DE reported thrombus progression (SOC 13.0% vs DE 5.1%) or stabilization (21.7% vs 10.3%), while more reported partial (34.8% vs 43.6%) or complete thrombus resolution (21.7% vs 35.9%). In the thrombophilia subgroup, BEs appeared to be lower in children treated with DE (SOC 26.1% vs DE 17.9%), while in the overall population BEs with SOC and DE were comparable. In the secondary VTE prevention trial, children with thrombophilia were also slightly older versus the overall population (mean [standard deviation] age 14.1 [3.6] vs 12.8 [4.6] yrs; p = 0.006). In this larger subgroup of children, rates of recurrent VTE at 12 months appeared to be higher in the thrombophilia group (2.8%) compared to the overall population (1.4%) (Table), with BEs largely comparable (27.4% and 22.5%, respectively). Conclusions: Unsurprisingly, numerically more children with thrombophilia appeared to report VTE recurrence, and in DIVERSITY thrombus progression/stabilization also seemed higher compared with the overall population. Compared with the overall populations, these subgroup analyses showed consistent results for DE in children with acute VTE and thrombophilia in the DIVERSITY trial, along with a favorable safety profile of DE for secondary VTE prevention. Disclosures Brandao: Boehringer Ingelheim: Other: Member of a paediatric expert working group. Tartakovsky:Boehringer Ingelheim: Current Employment. Albisetti:Boehringer Ingelheim: Other: Member of a paediatric expert working group; Daiichi Sankyo: Membership on an entity's Board of Directors or advisory committees. Bomgaars:Boehringer Ingelheim: Other: Member of a paediatric expert working group. Chalmers:CSL Behring: Honoraria; Shire/Takeda: Honoraria; Boehringer Ingelheim: Other: Member of a paediatric expert working group; Grifols: Honoraria; Roche: Honoraria; Sobi: Honoraria; Bristol-Myers Squibb: Honoraria. Mitchell:Boehringer Ingelheim: Other: Member of a paediatric expert working group. Luciani:Boehringer Ingelheim: Other: Member of a paediatric expert working group. Lvova:Boehringer Ingelheim: Honoraria. Simetzberger:Boehringer Ingelheim: Current Employment. Sun:Boehringer Ingelheim: Current Employment. Gergei:Boehringer Ingelheim: Current Employment. Brueckmann:Boehringer Ingelheim: Current Employment. Halton:Boehringer Ingelheim: Other: Member of a paediatric expert working group. OffLabel Disclosure: dabigatran etexilate in paediatric VTE
- Open Access
- 1 March 2014
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 60 (2) , 211-215
Anticoagulation Therapy Trends in Children Supported by Ventricular Assist Devices
Ventricular assist device (VAD) use in children has increased dramatically. There are currently few data regarding trends in anticoagulation management for pediatric VADs. A retrospective cohort study was conducted for patients with an International Classification of Diseases, Ninth Revision (ICD-9) code for VAD implantation from 2000 to 2011 from the Pediatric Health Information System database. Patient demographics, use of extracorporeal membrane oxygenation, orthotopic heart transplantation (OHT), disease states, and medications pertinent to the management of VAD anticoagulation were queried. Patients were grouped into 3 year time periods to evaluate trends in medication use over time. Four hundred sixty-six patients were identified with a median length of VAD therapy of 21 days (range 1-362 days). In-hospital mortality was 31.9%, and 54.5% underwent OHT. Length of VAD therapy and patients undergoing OHT increased, while mortality decreased. Patients received a median of two anticoagulant medications (range 0-6), one (range 0-4) antiplatelet medications, three (range 0-5) procoagulant medications, and one (range 0-3) antifibrinolytics. Patients received greater mean numbers of anticoagulant, procoagulant, antifibrinolytic, and antiplatelet agents, and the use of oral medications increased more than twofold over time. There is wide variability for in-hospital pediatric VAD anticoagulation management, with a significant increase in the use of oral agents in more recent years.
- 1 March 2014
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 60 (2) , 211-215
Open AccessAnticoagulation Therapy Trends in Children Supported by Ventricular Assist Devices
Ventricular assist device (VAD) use in children has increased dramatically. There are currently few data regarding trends in anticoagulation management for pediatric VADs. A retrospective cohort study was conducted for patients with an International Classification of Diseases, Ninth Revision (ICD-9) code for VAD implantation from 2000 to 2011 from the Pediatric Health Information System database. Patient demographics, use of extracorporeal membrane oxygenation, orthotopic heart transplantation (OHT), disease states, and medications pertinent to the management of VAD anticoagulation were queried. Patients were grouped into 3 year time periods to evaluate trends in medication use over time. Four hundred sixty-six patients were identified with a median length of VAD therapy of 21 days (range 1-362 days). In-hospital mortality was 31.9%, and 54.5% underwent OHT. Length of VAD therapy and patients undergoing OHT increased, while mortality decreased. Patients received a median of two anticoagulant medications (range 0-6), one (range 0-4) antiplatelet medications, three (range 0-5) procoagulant medications, and one (range 0-3) antifibrinolytics. Patients received greater mean numbers of anticoagulant, procoagulant, antifibrinolytic, and antiplatelet agents, and the use of oral medications increased more than twofold over time. There is wide variability for in-hospital pediatric VAD anticoagulation management, with a significant increase in the use of oral agents in more recent years.
- 16 February 2008
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 62 (6) , 1027-1037
Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children’s oncology group
Objective To develop a population pharmacokinetic model of irinotecan and its major metabolites in children with cancer and to identify covariates that predict variability in disposition. Methods A population pharmacokinetic model was developed using plasma concentration data from 82 patients participating in a multicenter Pediatric Oncology Group (POG) single agent phase II clinical trial. Patients between 1 and 21 years of age with solid tumors refractory to standard therapy received irinotecan, 50 mg/m2, as a 60-min intravenous infusion for 5 consecutive days every 3 weeks. Blood samples were collected and analyzed for irinotecan and three metabolites (SN-38, SN-38G, and APC). The population model was developed with NONMEM. Clearance and volume were scaled allometrically using corrected body weight. Exponential error models were used to describe the interindividual variance in pharmacokinetic parameters, and the residual error was described with a proportional model. Significant covariate effects were identified graphically using S-PLUS and were added to the base-model. The final model was evaluated by simulating data from two other POG trials. Results The best structural model for irinotecan and its metabolites consisted of six-compartments: two compartments for irinotecan and SN-38, and one each for APC and SN-38G. Age and bilirubin were found to be significant covariates affecting SN-38 clearance. SN-38 clearance was greater in patients less than 10 years of age and lower in patients with a total serum bilirubin >0.6 mg/dL. Simulations revealed that the model was able to predict drug and metabolite exposure (AUC) for patients receiving the same or similar doses (30–65 mg/m2) of irinotecan. Conclusions This population model accurately describes the pharmacokinetics of irinotecan and its primary metabolites. The model, which includes age and bilirubin as covariate effects on SN-38 clearance, is the first population model to describe the pharmacokinetics of irinotecan and its major metabolites in children.
- 16 February 2008
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 62 (6) , 1027-1037
Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children’s oncology group
Objective To develop a population pharmacokinetic model of irinotecan and its major metabolites in children with cancer and to identify covariates that predict variability in disposition. Methods A population pharmacokinetic model was developed using plasma concentration data from 82 patients participating in a multicenter Pediatric Oncology Group (POG) single agent phase II clinical trial. Patients between 1 and 21 years of age with solid tumors refractory to standard therapy received irinotecan, 50 mg/m2, as a 60-min intravenous infusion for 5 consecutive days every 3 weeks. Blood samples were collected and analyzed for irinotecan and three metabolites (SN-38, SN-38G, and APC). The population model was developed with NONMEM. Clearance and volume were scaled allometrically using corrected body weight. Exponential error models were used to describe the interindividual variance in pharmacokinetic parameters, and the residual error was described with a proportional model. Significant covariate effects were identified graphically using S-PLUS and were added to the base-model. The final model was evaluated by simulating data from two other POG trials. Results The best structural model for irinotecan and its metabolites consisted of six-compartments: two compartments for irinotecan and SN-38, and one each for APC and SN-38G. Age and bilirubin were found to be significant covariates affecting SN-38 clearance. SN-38 clearance was greater in patients less than 10 years of age and lower in patients with a total serum bilirubin >0.6 mg/dL. Simulations revealed that the model was able to predict drug and metabolite exposure (AUC) for patients receiving the same or similar doses (30–65 mg/m2) of irinotecan. Conclusions This population model accurately describes the pharmacokinetics of irinotecan and its primary metabolites. The model, which includes age and bilirubin as covariate effects on SN-38 clearance, is the first population model to describe the pharmacokinetics of irinotecan and its major metabolites in children.